This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

SGN-30

Seattle Genetics, Inc.

Drug Names(s): anti-CD30 mAb

Description: SGN-30 is a monoclonal antibody that targets the cell surface receptor CD30 that is expressed on many hematologic malignancies including Hodgkin's disease, certain leukemias and lymphomas, and in certain immunologic disease indications. SGN-30 is a genetically engineered monoclonal antibody that induces direct anti-cancer activity on its own.


SGN-30 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug